Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225152 | 1.00 | KMT2A (0.58) | KMT2ANPFFR2NPSR1ALDH1A1LMNA | |
| SCHEMBL2164856 | 1.00 | KMT2A (0.58) | KMT2ANPFFR2NPSR1ALDH1A1LMNA | |
| SCHEMBL17548936 | 0.83 | LMNA (0.49) | KMT2ANPFFR2NPSR1ALDH1A1LMNA | |
| SCHEMBL20745432 | 0.81 | SMN1; SMN2 (0.46) | KMT2ANPFFR2NPSR1ALDH1A1LMNA | |
| SCHEMBL2164811 | 0.81 | ALDH1A1 (0.46) | KMT2ANPFFR2NPSR1ALDH1A1LMNA | |
| SCHEMBL978767 | 0.81 | LMNA (0.47) | KMT2ANPFFR2NPSR1ALDH1A1LMNA | |
| SCHEMBL112321 | 0.81 | LMNA (0.47) | KMT2ANPFFR2NPSR1ALDH1A1LMNA | |
| SCHEMBL22613823 | 0.81 | SMN1; SMN2 (0.49) | KMT2ANPFFR2NPSR1ALDH1A1LMNA | |
| SCHEMBL22613822 | 0.81 | SMN1; SMN2 (0.49) | KMT2ANPFFR2NPSR1ALDH1A1LMNA | |
| SCHEMBL2164812 | 0.81 | ALDH1A1 (0.46) | KMT2ANPFFR2NPSR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111957063-B | Trapping device and process for 3, 4-dichlorobenzonitrile production | 常州新日催化剂股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-111957063-A | Trapping device and process for 3, 4-dichlorobenzonitrile production | 常州新日催化剂有限公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2366704-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2364984-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-3983246-A | N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents | FMC CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
| US-3941832-A | Oxime ethers and pesticidal preparations containing them | CIBA-GEIGY AG (CH) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | KMT2A 3222/4885NPFFR2 3659/4885NPSR1 1382/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | KMT2A 3222/4885NPFFR2 3659/4885NPSR1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.